Search Results - "Pujol, J"

The role of reactive oxygen species in homeostasis and degradation of cartilage by Henrotin, Y.E, Bruckner, P, Pujol, J.-P.L

“…Objectives: The metabolism of cells in articular joint tissues in normal and pathological conditions is subject to a complex environmental control. In addition…”
Get full text

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) by Gervais, R., Ducolone, A., Breton, J.-L., Braun, D., Lebeau, B., Vaylet, F., Debieuvre, D., Pujol, J.-L., Tredaniel, J., Clouet, P., Quoix, E.

“…Background: Taxotere® (docetaxel) at the dose of 75 mg/m2 every 3 weeks is a standard therapy for pretreated non-small-cell lung cancer (NSCLC). The aim of…”
Get full text

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial by Peters, S., Dafni, U., Dómine, M., Popat, S., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., López Vivanco, G., Madelaine, J., Faehling, M., Griesinger, F., González Larriba, J.L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Le Pechoux, C., De Ruysscher, D., Stahel, R., Hiltbrunner, A., Gasca-Ruchti, A., Giacomelli, N., Kammler, R., Marti, N., Pfister, R., Piguet, A.C., Roux, S., Troesch, S., Schweri, R., Zigomo, I., Tsourti, Z., Tsouprou, S., Kassapian, M., Vervita, K., Dimopoulou, G., Andriakopoulou, C., Morin, F., Amour, E., Mariaule, G., Archirel, N., Fernandez, M., Pereira, E., Benito, L., Lopez, K., Hernández, A., Chinchen, S., Jurkovic, H., Livingstone, A., Walker, M., Mitchell, P., Ng, S., Steer, C., Briscoe, K., Saqib, A., O’Byrne, K., Chittajallu, B.R., Hughes, B.G., Black, A., Nackaerts, K., Werner, H., Gervais, R., Zalcman, G., Monnet, I., Moro-Sibilot, D., Molinier, O., Girard, N., Souquet, P.-J., Barlesi, F., Debieuvre, D., Senellart, H., Poudenx, M., Dixmier, A., Pouessel, D., Cadranel, J., Lena, H., Quoix, E., Friard, S., Audigier-Valette, C., Mazieres, J., Pichon, E., Faehling, M., Kokowski, K., Griesinger, F., Tufman, A., de Langen, J., González Larriba, J.L., Insa, A., Massutí, B., Pulla, M.P., Aix, S.P., Villanueva, N., Andrade, J., Curioni-Fontecedro, A., Franks, K., Califano, R.

“…Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell…”
Get full text

Psoriasis dermatitis, a common phenotype of early forms of both psoriasis and atopic dermatitis in children: A prospective multicenter study by Docampo‐Simón, Alexandre, Belinchón, Isabel, Sánchez‐Pujol, María J., Berbegal, Laura, Miralles, Julia, Lucas, Ana, Quecedo, Esther, Fuertes, Amparo, Mateu‐Puchades, Almudena, Betlloch, Isabel

“…Background Psoriasis (Ps) and atopic dermatitis (AD) are chronic systemic immune‐mediated diseases that can coexist in an overlapping condition called…”
Get full text

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial by Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C.

“…IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. This…”
Get full text

Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients by Jacot, W., Colinet, B., Bertrand, D., Lacombe, S., Bozonnat, M.-C., Daurès, J.-P., Pujol, J.-L.

“…Both quality of life (QoL) and comorbidity influence therapy and prognosis of non-small-cell lung cancer (NSCLC). We previously developed a lung cancer…”
Get full text

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours by Jacot, W., Bessis, D., Jorda, E., Ychou, M., Fabbro, M., Pujol, J-L., Guillot, B.

Get full text

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index by COLINET, B, JACOT, W, BERTRAND, D, LACOMBE, S, BOZONNAT, M.-C, DAURES, J.-P, PUJOL, J.-L

“…Treatment of non-small-cell lung cancer (NSCLC) might take into account comorbidities as an important variable. The aim of this study was to generate a new…”
Get full text

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting by Daudén, Esteban, Escario, Elena, Martos-Cabrera, Luisa, Armesto, Susana, Herrera-Acosta, Enrique, Vidal, David, Vilarrasa, Eva, Rivera, Raquel, de la Cueva, Pablo, Martorell, Antonio, Ballesca, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero-Maté, Alberto, Pujol-Montcusí, J, Salgado, Laura, Sahuquillo-Torralba, Antonio, Coto-Segura, Pablo, Baniandrés, Ofelia, Feltes, R, Riera-Monroig, Josep, Garrido, Jesus, Llamas-Velasco, Mar

“…Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. The objective of the study was to determine…”
Get full text

Authors reply to letter to the editor by Dr Degens et al by Bommart, S., Pujol, J.-L., Coffy, A., Daurès, J.-P., Roch, B.

Get full text

High adherence to secukinumab in patients with moderate to severe psoriasis: a long‐term multicenter study in a daily practice setting by Martos‐Cabrera, Luisa, Llamas‐Velasco, Mar, Armesto, Susana, Herrera‐Acosta, Enrique, Vidal, David, Vilarrasa, Eva, Rivera‐Diaz, Raquel, Cueva, Pablo, Martorell‐Calatayud, Antonio, Ballescá, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero‐Maté, Alberto, Pujol‐Montcusí, J., Salgado‐Boquete, Laura, Sahuquillo‐Torralba, Antonio, Coto‐Segura, Pablo, Baniandrés, Ofelia, Feltes, R., Alsina, M., Daudén, Esteban

Get full text

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials by Scagliotti, G.V, Gridelli, C, de Marinis, F, Thomas, M, Dediu, M, Pujol, J.-L, Manegold, C, San Antonio, B, Peterson, P.M, John, W, Chouaki, N, Visseren-Grul, C, Paz-Ares, L.G

“…Highlights • Compared advanced NSCLC phase III trials: pemetrexed–cisplatin with or without pem maintenance. • 4 cycles pem–cis followed by pem maintenance…”
Get full text

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes by Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R.M., Vansteenkiste, J., Thatcher, N., Manegold, C., Pujol, J.-L., van Zandwijk, N., Gridelli, C., van Meerbeeck, J.P., Crino, L., Brown, A., FitzGerald, P., Aristides, M., Schiller, J.H.

“…Gemcitabine–platinum combination activity has been clearly established in a number of phase II studies. It has also been compared against other combinations in…”
Get full text

Reply to the letter to the editor ‘Flaws in the trial design of IFCT-0802’ by Gyawali et al by Pujol, J.-L., Morin, F., Zalcman, G.

Get full text

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent by PUJOL, J.-L, CARESTIA, DAURES, J.-P

“…Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug combinations and schedules remain to be defined and there is hitherto no…”
Get full text

Brain volumetric and metabolic correlates of electroconvulsive therapy for treatment-resistant depression: a longitudinal neuroimaging study by Cano, M, Martínez-Zalacaín, I, Bernabéu-Sanz, Á, Contreras-Rodríguez, O, Hernández-Ribas, R, Via, E, de Arriba-Arnau, A, Gálvez, V, Urretavizcaya, M, Pujol, J, Menchón, J M, Cardoner, N, Soriano-Mas, C

“…Recent research suggests that neuroplastic and neuroinflammatory changes may account for the mode of action of electroconvulsive therapy (ECT), although extant…”
Get full text

Intrasurgical mapping of complex motor function in the superior frontal gyrus by Martino, J, Gabarrós, A, Deus, J, Juncadella, M, Acebes, J.J, Torres, A, Pujol, J

“…Abstract A lesion to the superior frontal gyrus (SFG) has been associated with long-lasting deficits in complex motor functions. The aim of this study was to…”
Get full text

Prefrontal-amygdala connectivity in trait anxiety and generalized anxiety disorder: Testing the boundaries between healthy and pathological worries by Porta-Casteràs, D, Fullana, MA, Tinoco, D, Martínez-Zalacaín, I, Pujol, J, Palao, DJ, Soriano-Mas, C, Harrison, BJ, Via, E, Cardoner, N

“…•GAD participants presented an increased resting-state functional connectivity between left basolateral amygdala and vmPFC.•Non-GAD participants with low and…”
Get full text

Are chilblain‐like acral skin lesions really indicative of COVID‐19? A prospective study and literature review by Docampo‐Simón, A., Sánchez‐Pujol, M.J., Juan‐Carpena, G., Palazón‐Cabanes, J.C., Vergara‐De Caso, E., Berbegal, L., Poveda‐Montoyo, I., Pastor‐Tomás, N., Mataix‐Díaz, J., Terencio‐Alemany, C., Martínez‐Torres, A., Miralles‐Botella, J., Blanes‐Martínez, M., González‐Villanueva, I., Betlloch‐Mas, I.

Get full text

Potential safety issues with blood flow restriction training by Loenneke, J. P., Wilson, J. M., Wilson, G. J., Pujol, T. J., Bemben, M. G.

“…The focal point of previous literature was establishing the efficacy of blood flow restriction training with respect to muscular strength, muscular…”
Get full text